how to build your own site for free


Pubblicazioni FCSA dal 2012

DOCUMENTI DI CONSENSO INTERSOCIETARIO 

  • DOCUMENTO DI CONSENSO SULLA DIAGNOSTICA DI LABORATORIO PER I PAZIENTI IN TRATTAMENTO CON FARMACI ANTICOAGULANTI AD AZIONE DIRETTA della Società Italiana per lo Studio dell'Emostasi e della Trombosi (SISET), della Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche (FCSA), della Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica (SIBioC) e della Società Italiana di Patologia Clinica e Medicina di Laboratorio (SIPMeL). RIME-D-18-00041R1, 2019
  • Tripodi A, Ageno W, Ciaccio M, Legnani C, Lippi G, Manotti C, Marcucci R, Moia M, Morelli B, Poli D, Steffan A, Testa S. Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL. Blood Transfus. 2018 Sep;16(5):462-470. 
  • Documento di consenso FCSA, SIMeL, SIBioC e CISMEL sul monitoraggio di laboratorio dei nuovi farmaci anticoagulanti orali. Documento pubblicato su Riv Ital Med Lab 2013;9:131–133 https://link.springer.com/content/pdf/10.1007%2Fs13631-013-0014-2.pdf
  • Tripodi A, Di Iorio G, Lippi G, Testa S, Manotti C. Position paper on laboratory testing for patients taking new oral anticoagulants. Consensus document of FCSA, SIMeL, SIBioC and CISMEL1 Clin Chem Lab Med. 2012 Dec;50(12):2137-40

ARTICOLI SU RIVISTE INTERNAZIONALI

  • Tosetto A, Testa S, Palareti G, Paoletti O, Nichele I, Catalano F, Morandini R, Di Paolo M, Tala M, Esteban P, Cora' F, Mannino S, Maroni A, Sessa M, Castaman G. The effect of management models on thromboembolic and bleeding rates in anticoagulated patients: an ecological study. Intern Emerg Med. 2019 Jul 15. doi: 10.1007/s11739-019-02148-7. 
  • Poli D, Antonucci E , Ageno W, Bertù L, MigliaccioL, Martinese L, PilatoG, Testa S, Palareti G. Oral anticoagulation with VKAs or DOACs in very elderly patients with atrial fibrillation. results from the prospective multicenter START2 Register study . PlosOne 2019
  • S. Testa , C. Dellanoce, O. Paoletti, E. Cancellieri, R. Morandini, M. Tala, S. Zambelli, C. Legnani. Edoxaban plasma levels in patients with non-valvular atrial fibrillation: inter and intra-individual variability, correlation with coagulation screening test and renal function. Thromb Res 2019
  • Testa S, Legnani C, Antonucci A, Paoletti O, Dellanoce C,Cosmi B, PengoV,Poli D, Morandini R, Testa R, Tripodi A, Palareti G Drug Levels And Bleeding Complications In Atrial Fibrillation Patients Treated With Direct Oral Anticoagulants. J Thromb Haemost 2019 
  • Poli D, Antonucci E, PengoV, Grifoni E, Maggini M, Testa S, Lodigiani C, Insana A, Marongiu F, Paparo C,Bucherini E, Pignatelli P, Palareti G, on the behalf of the ItalianFederation of Anticoagulation Clinics. High risk for reoperation among patients with bioprosthetic heart valves and indication for long-term anticoagulation. Open Heart, 2018
  • Testa S, Ageno W, Antonucci E, Morandini R, Beyer-Westendorf J, Paciaroni M, Righini M, Sivera P, Verhamme P, Pengo V, Poli D, Palareti G. Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Events Registry. Intern Emerg Med 2018
  • Poli D, Antonucci E, Pengo V, Migliaccio L, Testa S, Lodigiani L, Coffetti N, Facchinetti R, Serricchio G, Falco P, Mangione C, Masottini S, Ruocco L, De Caterina R, Palareti G coordinator of START Registry, on the behalf of the Italian Federation of Anticoagulation Clinics. Mechanical Prosthetic Heart Valves: quality of anticoagulation and thromboembolic risk. The observationa lmulticentre PLECTRUM Study. Intern J Cardiol 2018
  • Testa S, Paoletti O, Cristina Legnani, Dellanoce C, Antonucci E, Cosmi B, Pengo V, Poli D,Morandi R, Testa R, Tripodi A and Gualtiero PalaretiPalareti G, Coordinator of START Registry. Low drug levels and thrombotic complications in high risk atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost 2018
  • Cini M, Legnani C, Cosmi B, Testa S, Dellanoce C, Paoletti O, Marcucci R, Poli D, Paniccia R, Pengo V, Tripodi A, Palareti G; START-Laboratory Register. Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START-Laboratory Register. International Journal of Laboratory Hematology, 2018
  • Palareti G, Antonucci E, Mastroiacovo D, Ageno W, Pengo V, Poli D, Testa S, Tosetto A, Prandoni P. ACCP score to assess the risk of bleeding during anticoagulation: application to real-life data from the START2-REGISTRY. J Thromb Haemost, 2018
  • Poli D, Antonucci E, PengoV, Grifoni E, Maggini M, Testa S, Lodigiani C, Insana A, Marongiu F, Paparo C,Bucherini E, Pignatelli P, Palareti G, on the behalf of the ItalianFederation of Anticoagulation Clinics. High risk for reoperation among patients with bioprosthetic heart valves and indication for long-term anticoagulation. Open Heart, 2018
  • Poli D, Antonucci E, Pengo V, Migliaccio L, Testa S, Lodigiani L, Coffetti N, Facchinetti R, Serricchio G, Falco P, Mangione C, Masottini S, Ruocco L, De Caterina R, Palareti G coordinator of START Registry, on the behalf of the Italian Federation of Anticoagulation Clinics. Mechanical Prosthetic Heart Valves: quality of anticoagulation and thromboembolic risk. The observationalmulticentre PLECTRUM Study. Internat J Cardiol 2018 
  • Palareti G, Antonucci E, Mastroiacovo D, Ageno W, Pengo V, Poli D, Testa S, Tosetto A, Prandoni P. ACCP score to assess the risk of bleeding during anticoagulation: application to real-life data from the START2-REGISTRY. J Thromb Haemost, 2018
  • Gentian D, Zoppellaro G, Padayattil Jose S, Antonucci E, Marongiu F, Poli D, Testa S, Tripodi A, Palareti G, Pengo V. Warfarin prescription in patients with non-valvular atrial fibrillation and one non-gender related risk factor (CHA2DS2VASc 1 or 2): a treatment dilemma. Cardiovascular Therapeutics, 2017
  • Poli D, Antonucci E, Pengo V, Testa S, Palareti G. Comparison of HAS-BLED and HAS-BED Versus CHADS2 and CHA2DS2VASC Stroke and Bleeding Scores in patients with atrial fibrillation. Am J Cardiol 2017 
  • Palareti G, Antonucci E, Migliaccio L, Erba N, Marongiu F, Pengo V, Poli D, Testa S, Tosetto A, Tripodi A, Moia M; on behalf of the centres participating in the FCSA-START-Register (The ISCOAT 2016 study). Vitamin K Antagonist Therapy: Changes in the Treated Populations and in Management Results in Italian Anticoagulation Clinics Compared with those recorded 20 years ago. Intern and Emerg Med, 2017 
  • Poli D, Antonucci E, Dentali F, Testa S, Palareti G; on the behalf of the Italian Federation of Anticoagulation Clinics (FCSA). Intracranial hemorrhage recurrence on vitamin K antagonist: severity of the first episode and HASBLED score fail to identify high-risk patients from the CHIRONE study. Blood Coagul Fibrinolysis. 2017 Jan;28(1):62-65. doi: 10.1097/MBC.0000000000000540.  
  • Cosmi B, Legnani C, Ghirarduzzi A, De Micheli V, Pengo V, Testa S, Poli D, Antonucci E, Prisco D, Tripodi A, Prandoni P, Palareti G; FCSA, Italian Federation of Anticoagulation Clinics. OC-15 - Risk factors for cancer development after idiopathic venous thromboembolism. Thromb Res. 2016 Apr;140 Suppl 1:S174. doi: 10.1016/S0049-3848(16)30132-3. 
  • Palareti G, Antonucci E, Lip GY, et al .The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. A real-life inception cohort study. Thromb Haemost 2016 
  • Testa S, Legnani C, Tripodi A, et al. Poor comparability of coagulation screening test with specific measurement in patients on direct oral anticoagulants: results from a multicenter/multiplatform study. J Thromb Haemost 2016 
  • Testa S, Tripodi A, Legnani C, et al; START-Laboratory Register. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics. Thromb Res 2016 
  • Tosetto A, Manotti C, Marongiu F; Italian Federation of Anticoagulation Clinics (FCSA) clinical quality study group. Center-Related Determinants of VKA Anticoagulation Quality: A Prospective, Multicenter Evaluation. PLoS One. 2015 Dec 4;10(12):e0144314. doi: 10.1371/journal.pone.0144314. 
  • Barcellona D, Luzza M, Battino N, Fenu L, Marongiu F. The criteria of the Italian Federation of Thrombosis Centres on DOACs: a "real world" application in  nonvalvular atrial fibrillation patients already on vitamin K antagonist. Intern  Emerg Med. 2015 Mar;10(2):157-63. 
  • Antonucci E, Poli D, Tosetto A, Pengo V, Tripodi A, Magrini N, Marongiu F, Palareti G; START-Register. The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation. PLosOne 2015 
  • Poli D, Antonucci E, Dentali F, Erba N, Testa S, Tiraferri E, Palareti G; Italian Federation of Anticoagulation Clinics (FCSA). Recurrence of ICH after resumption of anticoagulation with VK antagonists: CHIRONE study. Neurology. 2014 Mar 25;82(12):1020-6. 
  • Pengo V, Marongiu F; Members of the Steering Committee of the Italian Federation of Thrombosis Centers FCSA. Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a reply to a rebuttal. J Thromb Haemost. 2013 Jun;11(6):1205-6. 
  • Poli D, Antonucci E, Testa S, Cosmi B, Palareti G, Ageno W; FCSA Italian Federation of Anticoagulation Clinics. The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study. J Thromb Haemost. 2013 Jun;11(6):1053-8. 
  • Cosmi B, Legnani C, Pengo V, Ghirarduzzi A, Testa S, Poli D, Prisco D, Tripodi A, Palareti G; PROLONG Investigators (on behalf of FCSA, Italian Federation of Anticoagulation Clinics). The influence of factor V Leiden and G20210A prothrombin mutation on the presence of residual vein obstruction after idiopathic deep-vein thrombosis of the lower limbs. Thromb Haemost. 2013 Mar;109(3):510-6. doi: 10.1160/TH12-01-0041. 
  • Poli D, Antonucci E, Testa S, Ageno W, Palareti G; FCSA (Italian Federation of Anticoagulation Clinics). Gender differences of bleeding and stroke risk in very old atrial fibrillation patients on VKA treatment: results of the EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics). Thromb Res. 2013 Jan;131(1):12-6. 
  • Tripodi A, Di Iorio G, Lippi G, Testa S, Manotti C. Position paper on laboratory testing for patients taking new oral anticoagulants. Consensus document of FCSA, SIMeL, SIBioC and CISMEL1). Clin Chem Lab Med. 2012 Dec;50(12):2137-40. PubMed PMID: 23093266. 
  • Poli D, Antonucci E, Zanazzi M, Grifoni E, Testa S, Ageno W, Palareti G. Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics). Thromb Haemost. 2012 Jun;107(6):1100-6. 
  • Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G, Poli D, Testa S, Tiraferri E, Tosetto A, Tripodi A, Manotti C; Italian Federation of Thrombosis Centers. Questions and answers on the use of dabigatran and perspectives on the use of other new oral Anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost. 2011 Nov;106(5):868-76
  • Marongiu F, Finazzi G, Pengo V, Poli D, Testa S, Tripodi A. Management of special conditions in patients on vitamin K antagonists. Intern Emerg Med. 2012 Oct;7(5):407-13. Epub 2011 May 27. Review. 

SUBMITTED ARTICLE

  • Poli D, Antonucci E ,Bertù L, Vignini E, Ruocco L, Mastroiacovo D, Paparo C, Pastori D, Testa S, Ageno W, Palareti G. Veryelderlypatients with venousthromboembolism on oralanticoagulation with VKAS or DOACS: results from the prospectivemulticenter START2-Register Study(Major Revision)
  • Palareti G, Antonucci E, Dentali F, Mastroiacovo e Mumoli N, Pengo V, Poli D,Imberti D, Fontanella F.Patients with IsolatedPulmonaryEmbolism in Comparison to those with DeepVenousThrombosis. Differences in Characteristics and Clinical Evolution (submitted)

GUIDE PRATICHE

  • FCSA. Le Terapie Anticoagulanti in tasca. Indicazioni pratiche a cura di FCSA 2019
  • FCSA. Pazienti in terapia anticoagulante orale cosa fare in caso di: emorragia intracranica, emorragia maggiore, emorragia non maggiori clinicamente rilevanti e minori, correzione di eccessiva anticoagulazione in assenza di emorragie. Indicazioni pratiche a cura di FCSA 2019
  • FCSA. Guida alla terapia antitrombotica . XVI edizione 2018
  • FCSA. Guida alla terapia antitrombotica . XVI edizione 2017
  • FCSA. Guida alla terapia antitrombotica . XV edizione 2016
  • FCSA. Guida alla terapia antitrombotica . XIV edizione 2015
  • FCSA. Guida alla terapia antitrombotica . XIII edizione 2014
  • FCSA. Guida alla terapia antitrombotica . XII edizione 2013
  • FCSA. Guida alla terapia antitrombotica . XI edizione 2012

FCSA ringrazia per il contributo incondizionato

Segreteria

Via Maestro G. Capocci, 11              
00199 Roma
E-mail: fcsa@fcsa.it 
Telefono: +39 391 7052644

Sede Legale

Via Manfredo Camperio, 14
20123 Miano                  
c/o BC& Studio Consulenza Societaria Tributaria Legale